Somatoprim: Phase IIa started

Aspireo began an open-label, Ukrainian Phase IIa trial to evaluate single ascending-doses of 100, 300, 900 and 1,800 µg subcutaneous Somatoprim in combination with 300 µg octreotide in up to 20 untreated acromegaly patients. ...